



## Bio-statistical Analysis in Bioequivalence studies

Hrushikesh Suresh Shinde  
Biostatistician, Pune, Maharashtra.  
Email: [shinde.hrushikesh014@gmail.com](mailto:shinde.hrushikesh014@gmail.com)

Received 02 Sep., 2023; Revised 12 Sep., 2023; Accepted 14 Sep., 2023 © The author(s) 2023.  
Published with open access at [www.questjournals.org](http://www.questjournals.org)

**Keywords:** Pharmacokinetic; Bioequivalence studies; Statistical analysis; ANOVA

### Abbreviations:

BE	Bioequivalence
BA	Bioavailability
ANOVA	Analysis of Variance
C <sub>max</sub>	Maximum Plasma Concentration
AUC	Area Under the Curve
AUC <sub>0-t</sub>	Area Under the Curve from time zero to time of last measurable concentration.
SAS	Statistical Analysis Software
R	R Software
PK	Pharmacokinetic Parameters

### I. Introduction:

In order to compare the rate and extent of absorption of two or more formulations, bioequivalence studies are recommended.

The study objective of bioequivalence studies is -

Primary Objective: To assess bioequivalence of the Test product in Comparison with Reference Product.

Secondary Objective: To assess safety and tolerability of the test product in Comparison with the Reference product.

The goal of these studies is to present evidences of similar bioavailability [1].

In many countries, these studies are necessary for the commercialization of generic drugs.

The Pharmacokinetic parameters are calculated using a non -compartmental model using SAS / R / Phoenix Winnonlin / Other Software.

PK parameters are leads to a comparison of relative bioavailability [2].

Generally, the pharmacokinetic parameters considered in a bioequivalence study are the Maximum Concentration (C<sub>max</sub>) and the Area under the plasma concentration curve (AUC<sub>0-t</sub>) at a previously defined time. These parameters are obtained directly from the plasma concentration curve of each individual, for each study formulation [3].

Statistical analysis of PK Parameters is performed using SAS / R / Phoenix Winnonlin / Other Software.

The Statistical analysis are including: a) Descriptive Statistics; b) ANOVA; c) Power analysis; d) Ratio analysis e) Acceptance criteria for bioequivalence [4].

a) Descriptive Statistics:

The Calculated PK parameters are tabulated for each subject –product combination wise. Descriptive statistics for untransformed data of all PK Parameters and geometric least square mean and intra CV % for log natural transformed data (primary PK parameters) for test and reference products.

b) ANOVA:

In bioequivalence study used Schuirmann's two one-sided ANOVA tests procedure. ANOVA are performed on natural log transformed for Primary PK parameters.

c) Power analysis:

The power of the test to detect at least a 20% mean difference between test and reference formulations are reported.

d) Ratio analysis:

Ratio calculations using the least squares mean of the Ln-transformed primary PK Parameters are performed for bioequivalence assessment. The comparison of interest is Test product vs Reference product.

e) Acceptance criteria for bioequivalence:

The test product is considered bioequivalent to reference product, if 90% confidence intervals for ratio (test/reference) of geometric least square means based on log transformed primary PK parameters fall within acceptance BE limits of 80.00% to 125.00%.

**References:**

- [1]. Hyslop T, Hsuan F, Holder DJ (2000) A small sample confidence interval approach to assess individual bioequivalence. *Stat Med* 19(20): 2885- 2897.
- [2]. *International Journal of Research Studies in Biosciences (IJRSB)*
- [3]. Metzler CM (1974) Bioavailability - a problem in equivalence. *Biometrics* 30(2): 309-317.
- [4]. *Statistical Approaches to Establishing Bioequivalence Guidance for Industry*